We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
12 own
15 watching
Current Price
$0
$0.12
(10.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
76.64M
52-Week High
10.39
52-Week Low
0.4899
Average Volume
0.25M
Dividend Yield
--
P/E Ratio
--
Market Capitalization76.64M
52-Week High10.39
52-Week Low0.4899
Average Volume0.25M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Accesswire
14days ago
GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / November 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) (' Relief '), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (' NRx Pharmaceuticals '), today announced that they have entered into definitive...
PR Newswire
14days ago
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements PR Newswire GENEVA and RADNOR, Pa., Nov. 14, 2022 Ad hoc...
Accesswire
3 months ago
GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / August 22, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ('Relief'), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ('NRx'), today announced that they have agreed to a tentative settlement of their...
Globe Newswire
3 months ago
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NRx Pharmaceuticals, Inc. (NRx or the Company) (NASDAQ:NRXP;NRXPW). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
PR Newswire
3 months ago
Thinking about buying stock in Ford Motor, Missfresh, Intel Corp, Ontrak, or NRX Pharmaceuticals? Thinking about buying stock in Ford Motor, Missfresh, Intel Corp, Ontrak, or NRX Pharmaceuticals? PR Newswire NEW YORK, Aug. 1, 2022 NEW YORK, Aug. 1, 2022 /PRNewswire/ -- InvestorsObserverissues...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.12
(10.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00